European Journal of Heart Failure Journal
Overview
Publication venue for
- Better pharmacotherapy in heart failure with reduced ejection fraction may partly explain the obesity paradox 2023
- Weighing in on weight loss in heart failure with reduced ejection fraction 2023
- Impact of trends in body mass index on outcomes in patients receiving HeartMate 3. 24:150-150. 2022
- The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. 23:1673-1676. 2021
- Cardiorespiratory fitness, body mass index and heart failure incidence. 21:436-444. 2019
- Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again?. 20:501-503. 2018
- Muscling up to improve heart failure prognosis. 20:1588-1590. 2018
- Obesity and mortality risk in heart failure: when adipose tissue distribution matters. 20:1278-1280. 2018
- Observations on the blood pressure paradox in heart failure. 19:843-845. 2017
- Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. 18:1072-1081. 2016
- A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. 16:483-493. 2014
- Heart rate recovery after the 6 min walk test rather than distance ambulated is a powerful prognostic indicator in heart failure with reduced and preserved ejection fraction: a comparison with cardiopulmonary exercise testing. 15:519-527. 2013
Identity
International Standard Serial Number (ISSN)
- 1388-9842